



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in application of:) Attorney Docket No.
Timo Kars van den Berg et al.) 080743235001
Serial No.: 10/007,275)
Filed: October 26, 2001)
For: METHOD FOR INHIBITING CELL)
FUNCTIONING FOR USE IN ANTI-)
INFLAMMATORY AND ANTI-)
TUMOR THERAPIES)
Examiner: Yaen, Christopher H.)
Group Art Unit: 1642)
Confirmation No.: 5284)

RECEIVED

JUL 07 2003

TECH CENTER 1600/2300

AMENDMENTS TO THE SPECIFICATION

Amend paragraph 0027 to read as follows:

AA
The rat macrophage cell line NR8383 (Adams et al. 1998) are cultured at a density of 0.25×10^6 cells/ml in a 96-well cell culture plate in RPMI-1640 medium containing 2% fetal calf serum and 2 mM glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin. This is performed in the presence (or absence) of anti-SIRP Fab-fragments (ED9 or ED17; 40 μ g/ml) or control Fab-fragments (OX41; 40 μ g/ml). After 24 h 3 H-thymidine (1 μ Ci/well) is added and the cells are incubated for another 6 hours. The cells are harvested using a cell harvester and cell incorporated radioactivity is determined in a Micro- β -plate reader. The mean results are shown in Table 1 below in Table 1:

Table 1

Treatment	Mean (in c.p.m.)	SD (standard dev.)
control	132783	2730
ED17 Fab	6845	197
OX41 Fab	154889	8528

AI *Amend* *Amend* paragraph 0029 to read as follows: *[*

AJ
To examine the effects of ED9 or ED17 Fab on myeloid cell division, NR8383 cells are assayed as described in the macrophage division test. (Note to Examiner - previous underline is in original document and is not part of this amendment.) As illustrated in Table 1 ~~table 1~~, ED 17 ~~ED~~ strongly inhibits division (analyzed by thymidine incorporation), whereas OX41 Fab has little effect.